Methamphetamine, an amphetamine derivative, is a powerful psychomotor stimulant and commonly used drug of abuse. This study examined the effect of binge-like methamphetamine (MA) dosing (4 × 4 mg/kg, s.c., 2 h apart) on regional dopamine and dopaminergic metabolite levels in rat brain at a range of early time points after final dose (2-48 h). Body temperature was elevated when measured 2 h after the last dose. MA increased dopamine levels in the frontal cortex 2 and 24 h after the last dose. The dopamine level was also increased in the amygdala at 24 h. No change was observed in the striatum at any time point, but levels of the dopamine metabolite DOPAC were markedly reduced at 24 and 48 h. Tyrosine hydroxylase expression is induced downstream of dopamine activity, and it is the rate limiting enzyme in dopamine synthesis. The effect of MA binge-like dosing on the volume of tyrosine hydroxylase containing cell bodies and the area fraction of tyrosine hydroxylase containing fibres was also assessed. MA increased the area fraction of tyrosine hydroxylase fibres in the frontal cortex and reduced the volume of tyrosine hydroxylase containing cell bodies 2 h after last dose in the ventral tegmental area and the substantia nigra. An increase in cell body volume in the substantia nigra was observed 48 h after treatment. These findings collectively highlight the importance of the dopaminergic system in methamphetamine induced effects, identify the frontal cortex, amygdala and striatum as key regions that undergo early changes in response to binge-like methamphetamine dosing and provide evidence of time-dependent effects on the cell bodies and fibres of tyrosine hydroxylase expressing neurons.
Introduction
Methamphetamine (MA), a synthetic derivative of amphetamine, is a very potent psychomotor stimulant and is well known for its high potential for abuse. MA intake by an array of routes of administration results in wide distribution in the periphery and the brain, where it interacts and reverses the function of mono-amine transporters, enhancing synaptic levels of dopamine, noradrenaline and serotonin (Cruickshank and Dyer, 2009) . Evidence suggests that the mechanism underlying the psychomotor and neurotoxic properties of amphetamine and MA are similar and they also have similar potency (Han and Gu, 2006; Levi et al., 2012) . Using in vivo microdialysis, it has been demonstrated that amphetamine and other amphetamine-like stimulants including MA rapidly increase extracellular levels of dopamine in dopamine-rich brain regions such as the striatum (Zetterstrom et al., 1983; Imperato and Di Chiara, 1984; O'Dell et al., 1991) . Depletion of dopamine days after drug exposure is another well-established feature of MA and amphetamine-like drugs of abuse (Dackis and Gold, 1985; Metzger et al., 2000; Matuszewich and Yamamoto, 2004; Quinton and Yamamoto, 2006; Atianjoh et al., 2008) , however dopamine tissue levels in the hours immediately following the rapid increase in extracellular levels, within the first 48 h after drug exposure is less widely investigated, and is the subject of the present study.
It has been suggested that low doses of MA affect the CNS by activation of D2 receptors, while high doses additionally activate D1 receptors (Alburges et al., 2001a; Alburges et al., 2001b) . Following stimulation of D1-like receptors, the subsequent increase in cAMP and influx of calcium activates protein kinase A, which can phosphorylate cAMP response element binding protein (CREB). It is known that drugs such as amphetamine and cocaine activate D1 receptors and induce phosphorylation of CREB (Dudman et al., 2003) . Phosphorylated CREB acts as a transcriptional factor for many downstream genes such as tyrosine hydroxylase (Piech-Dumas and Tank, 1999) .
Tyrosine hydroxylase is an enzyme that catalyses the conversion of L-tyrosine to L-DOPA. It is the rate-limiting enzyme in the synthesis of dopamine and noradrenaline. Many studies have shown an alteration in tyrosine hydroxylase following MA exposure. For example, a transient increase in tyrosine hydroxylase mRNA has been demonstrated in the rat locus coeruleus following acute MA treatment (Shishido et al., 1997) and an increase in tyrosine hydroxylase protein was observed in the mouse cerebellar cortex 3 days after a binge MA dosing regimen that correlated with the motor dysfunction caused by the drug (Ferrucci et al., 2007) . In contrast, chronic use of MA has been shown to cause a decrease in tyrosine hydroxylase levels (Kogan et al., 1976; Di Monte et al., 1996) that may be persistent (Hotchkiss and Gibb, 1980) and post-mortem studies of chronic MA users have shown reduced dopamine levels and tyrosine hydroxylase expression in the striatum (Wilson et al., 1996) .
Animal models have shown that single or repeated doses of methamphetamine promotes behavior and biochemical changes. Single large doses of methamphetamine up to 15 mg/kg have been used (Brown et al., 2002) , although recent studies (Good and Radcliffe, 2011; Braun et al., 2011) have demonstrated that repeated lower doses reduce risk of mortality and more closely mimics that used by humans. A regimen using 4 injections of methamphetamine at 2 h intervals is the most common approach (Taraska and Finnegan, 1997; Wallace et al., 1999; Pereira et al., 2006) . Dopaminergic fibres project to the striatum (nigrostriatal pathway), the cerebral cortex (mesocortical pathway) and the limbic system (mesolimbic pathway). There is considerable literature on the effects of MA in the striatum, but less information on the mesocortical and mesolimbic target sites. This study investigated the early effect of bingelike MA dosing on dopamine neurotransmitter levels in the frontal cortex and the amygdala, in addition to the striatum, at time points from 2 h after final binge dose, up to 48 h. The effect of MA binge dosing on neurons expressing tyrosine hydroxylase over the same time period was also assessed, specifically the cell body volume of neurons in the substantia nigra and ventral tegmental area, and the area fraction of tyrosine hydroxylase containing fibres in the frontal cortex. The acute hyperthermia triggered by MA has been associated with deficits in the dopaminergic system, oxidative stress and ultimately with neurodegeneration (Krasnova and Cadet, 2009) , so it was of interest to correlate the changes in dopaminergic neurons with changes in body temperature to advance understanding of the effect of methamphetamine on dopaminergic neurons.
Materials and methods
Sprague Dawley rats (250-350 g) were used in this study. Procedures were carried out under the guidelines of the Animal Welfare Committee of the National University of Ireland, Galway and in accordance with the EU Directive (2010/63/EU).
Rats (n = 6 or 7 per time point) were housed singly and maintained on a 12 h light/dark cycle (lights on at 08:00 h and off at 20:00 h). The housing facility was temperature (20°C ± 2°C) and humidity (40-60%) controlled. Food and water were available ad libitum.
(+) Methamphetamine-HCl was purchased under license from Sigma-Aldrich, USA. Rats were administered four doses of MA, 4 mg/ kg s.c. (calculated as free base), 2 h apart or saline for control. Repeated dosing of MA at 2 h intervals is commonly used to mimic binge-like drug taking behavior (Braun et al., 2011; Wallace et al., 1999; Pereira et al., 2006) . The 4 mg/kg dose used in this study was previously shown to be the highest safe level in our hands (data not shown).
Body temperature was measured in animals treated with methamphetamine and the saline treated controls by rectal thermometer at 2, 24 or 48 h after the last dose, immediately prior to sacrifice and brain dissection for analysis.
Concentrations of dopamine, its metabolites and 1-3-4-dihydroxyphenylamine (L-DOPA) were measured by HPLC with electrochemical detection using the method of (Seyfried et al., 1986) . Briefly, each brain was dissected on ice into regions of interest (frontal cortex, amygdala and striatum) and stored at -80°C until further processing. The fresh frozen brain tissue (n = 7 per group) was sonicated in ice cold homogenizing buffer, and the supernatant separated on a Merck Licrosorb RP-C18 column. N-Methyl-5-HT (2 ng/20 μl) was used as the internal standard in all samples. An external standard mix containing 200 ng/ 20 μl of dopamine, L-DOPA, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) was run between every 5 samples to recalibrate the system and minimize any drift in amine retention times as sampling proceeded. Peak height data from chromatograms together with data obtained from brain tissue weights and internal and external standard mixtures were used to calculate neurotransmitter concentration in each brain sample in terms of ng/g of fresh tissue.
For immunohistochemistry, animals (n = 6 per group) were deeply anaesthetized with pentobarbital and transcardial perfusion was performed with 4% v/v paraformaldehyde. The brains were stored in 20% w/v sucrose in PBS with 0.1% w/v sodium azide at 4°C. Coronal brain sections of 40 μM thickness were cut on a microtome and floated in Trizma Buffered Saline (TBS) with 1% w/v azide solution. Sections were washed with TBS (3 × 5 min), placed in 0.75% v/v hydrogen peroxide/methanol in distilled water for 5 min in order to quench the endogenous peroxides in the tissue, followed by further washes in TBS (3 × 5 min). Sections were then blocked with 3% v/v normal horse serum in Triton-X TBS (TXTBS) for 60 min, to avoid unspecific binding. Then sections were incubated for 24 h at room temperature and constant agitation in TXTBS containing tyrosine hydroxylase antibody (mouse, anti-rat; 1:1000 dilution, Vector Laboratories) and 1% v/v normal horse serum. After incubation, sections were washed in TBS (3 × 10 min) and incubated for 3 h in TBS containing biotinylated horse anti-mouse secondary antibody (1:200 dilution; Vector Laboratories) in 1% v/v normal horse serum. After incubation, sections were rinsed in TBS (3 × 10 min) and incubated in avidin-biotin-peroxidase complex (ABC) in TBS 1% v/v normal horse serum for 2 h. Sections were then rinsed in TBS (3 × 10 min) and incubated for 5 min in 0.02% 3,3-diaminobenzidine-4HCl (DAB) and 0.01% v/v H 2 O 2 in TBS to reveal immunoreactivity. The reaction was stopped by washing the section in TBS (3 × 5 min). The sections were then mounted on glass-gelatinised slides and air-dried overnight. Sections were then dehydrated in a series of ethyl alcohol (5 min in 50% alcohol, two times 5 min in 70% alcohol and 5 min in 100% alcohol), cleared with xylene (2 × 5 min) and coverslipped with DePex mounting medium.
Quantification of tyrosine hydroxylase fibres in the frontal cortex
Photomicrographs (20× magnification; five images per slice, six per animal) of the prefrontal cortex (region Fr2, interaural 13.7 mm, bregma +4.7 mm, (Paxinos and Watson, 1986) ) were analysed. Tyrosine hydroxylase fibre area was determined using Image J software. For this, images were first converted to gray scale 8-bit images, threshold defined and the area fraction of stained fibres was assessed by dividing by the area of the field of view.
Estimation of nuclear volume of tyrosine hydroxylase containing neurons in the Substantia Nigra (SN) and Ventral Tegmental Area (VTA)
Photomicrographs (20×; two images from each hemisphere) of the substantia nigra (pars reticulata and pars compacta) and ventral tegmental area were analysed. Volume-weighted mean volume (V v Nuc), was estimated as described by (Dockery et al., 1997) , and is an estimate of cell body volume. Briefly, this was determined by the point sampled intercept method (Gundersen et al., 1988) . A lattice of test points on lines was superimposed randomly onto the cell bodies in each particular field. When a point hit a cell body, a line was drawn through the point from one cell body margin to the other. These lines produced pointsampled intercepts whose length were measured in cm, changed to μm and divided by the magnification of the picture (in this case 500), to give the real size (l o ). The number was then cubed and the mean multiplied by π/3. The average overall intercepts gave an unbiased estimate of the cell body volume volume (V v Nuc;
All photomicrographs were taken at level Interaural 4.2 mm; bregma −4.8 mm, (Paxinos and Watson, 1986) ). Statistical comparisons were made by performing analysis of variance (one-way ANOVA). Inter-group comparisons were assessed using Dunnett's multiple comparisons post-hoc test. Results were expressed as mean ± standard error of the mean (S.E.M) on graphs and mean ± standard deviation (SD) on tables.
Results
Results showed a significant main effect on dopamine in the frontal cortex (F (3, 4) = 13.76; p < 0.0001; Fig. 1a) , with a significant increase in dopamine evident at 2 h (p < 0.001) and 24 h (p < 0.01), returning to normal by 48 h following MA binge-dosing. No change in dopamine expression was observed in the striatum (F (3,4) = 2.30; p > 0.05, Fig. 1b ). There was a significant main effect on dopamine levels in the amygdala (F (3, 4) = 6.87, p < 0.01; Fig. 1c) , with a significant increase in dopamine 24 h after final MA dose, but not any other time point.
No changes in the levels of the dopamine precursor L-DOPA, or the dopamine metabolite HVA was observed in the frontal cortex (L-DOPA: F (3, 4) = 1.78, p > .05; HVA: F (3, 4) = 0.42, p > .05), striatum (L-DOPA: F (3, 4) = 5.35, p > .05; HVA: F (3, 4) = 0.37, p > .05), or amygdala (L-DOPA: F (3,4) = 1.14, p > .05; HVA: F (3, 4) = 1.10, p > .05) at any time point following MA treatment (Table 1) . However, there was a significant main effect on DOPAC levels in the striatum (F (3, 4) = 226.9, p < .001). DOPAC levels were significantly reduced in the striatum 24 h (p < .001) and 48 h (p < .05) following binge-like MA treatment (Table 1) , but no significant change was observed in the frontal cortex (F (3, 4) = 0.93, p > .05) or amygdala (F (3, 4) = 0.37, p > .05).
The effect of the changes in dopamine and its metabolite levels on dopamine turnover rate were assessed using the formula [DOPAC] + (Zinszner et al., 1998)/[Dopamine] . The most pronounced changes in dopamine turnover were observed in the frontal cortex and striatum. In the frontal cortex, dopamine turnover was markedly reduced (approx. 4 -fold reduction) in MA treated animals, 2 h and 24 h after MA treatment (Table 2 ), but had recovered by 48 h. This change in turnover was due to the higher levels of dopamine in the frontal cortex at those time points after MA dosing (Fig. 1a) , while DOPAC and HVA levels were relatively unaffected (Table 1) . MA treatment also markedly affected dopamine turnover in the striatum, 24 h after MA treatment (also approaching 4 -fold reduction; Table 2), which had recovered by 48 h. This change in turnover was attributable to the substantially reduced DOPAC levels in the striatum observed at that time point (Table 1) . Dopamine turnover was also reduced in the amygdala 24 h after MA treatment, but the change was less pronounced (Table 2 ) and was largely caused by increased dopamine levels (Fig. 1c) at that time point.
As expected, a significant main effect on body temperature was observed (F (3, 4) = 49.98; p < 0.001; Fig. 2) , with a significant increase 2 h after the last dose that returned back to normal levels by the 24 h time point (Fig. 2) .
There was a significant main effect on the volume (V v Nuc) of tyrosine hydroxylase cell bodies both in the substantia nigra (F (3, 4) = 18.15, p < 0.01; Fig. 3a ) and the ventral tegmental area (F (3, 4) = 5.60, p < 0.05; Fig. 3b) . In both regions, cell body volume was significantly decreased 2 h after the MA regimen (4 doses 2 h apart), (Fig. 3a and b) . In the ventral tegmental area, levels of V v Nuc were back to normal by 24 h and no change was observed at 48 h (Fig. 3b) . In the substantia nigra levels were also back to normal by 24 h but an increase was observed in the V v Nuc 48 h after the last dose of MA Results were analysed by One Way ANOVA followed by Dunnett's post hoc analysis and are expressed as mean ± SD (n = 7). *p < 0.05, **p < 0.001 vs control.
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regimen (p < 0.01; Fig. 3a) . MA had a significant main effect on the area fraction of tyrosine hydroxylase fibres in the frontal cortex, (F (3, 4) = 4.25, p < 0.05; Fig. 4 ). The area fraction increased 2 h after MA treatment but returned back to normal level by 24 h and no change was seen at 48 h (Fig. 4) .
Discussion
MA rapidly increases extracellular levels of dopamine by reverse transport through the dopamine transporter (DAT) (Goodwin et al., 2009) . Additionally, Animal models have shown that MA causes a conformational change in the Vesicular Monoamine Transporter 2 (VMAT-2), resulting in the redistribution of neurotransmitter from synaptic vesicles to the cytosol (Fleckenstein et al., 2009 ). The literature also contains many studies which have shown a subsequent decrease in dopamine following MA administration when measured many days after the last dose (Hotchkiss and Gibb, 1980; Wallace et al., 1999; Hotchkiss et al., 1979; Woolverton et al., 1989) .
The results presented here could reflect a short-term increase in dopamine expression in order to support the effect on release of dopamine by MA in the initial hours after drug use. The short -lived increase observed was particularly evident in the frontal cortex, which is an area not well studied following MA dosing Dopamine levels measured in control animals in this study are in line with those previously reported in the literature (Fitoussi et al., 2013) . Previous studies using microdialysis have shown that MA increases extracellular DA levels (O'Dell et al., 1991; O'Dell et al., 1993; Nash and Yamamoto, 1992) and the literature also demonstrates that MA has been shown to produce long-lasting depletion of striatal dopamine (DA) resulting from damage to mesostriatal terminals (Hotchkiss et al., 1979; Wagner et al., 1980; Seiden et al., 1988) Most of these studies have focused on timepoints later than our study, normally 7 days after injection. The present study was not design to observed dopamine levels later than 48 h which may can explane the diference from the literature. Concerns about the neurotoxicity of methamphetamine following repeated administration are very well documented (Wallace et al., 1999; Ernst et al., 2000; Riddle et al., 2006) .Methamphetamine has been shown to induce toxicity in vivo and in vitro (Wallace et al., 1999) affecting in particular, but not only, dopaminergic neurons (Jang et al., 2007) . Many studies have shown that the psychological and neurotoxic effects are related to dopamine release (Matuszewich and Yamamoto, 2004; Albertson et al., 1999; Bamford et al., 2008) although the molecular and cellular mechanisms involved in this process remain to be clarified.
Dopamine turnover was reduced to the most pronounced extent in the frontal cortex and the striatum, although there was a reduction in turnover in all three regions at different time points. The change in dopamine turnover in the frontal cortex and amygdala was associated with the raised dopamine levels in brain tissue, but reduced DOPAC levels were the main contributary factor to the reduced dopamine turnover observed in the striatum. DOPAC and HVA are main metabolites of dopamine following the combined action of monoamine oxidase and catechol-O-methyl transferase (COM-T). DOPAC levels were reduced in the striatum at 24 and to a lesser extent, 48 h after dosing. Ordinarily, DOPAC is metabolised to HVA by COM-T, but can also be oxidised by hydrogen peroxide to produce toxic metabolites such as peroxynitrite (Imam et al., 1999) . There was no significant change in HVA in any brain region, including the striatum, at any time point in this study. Understanding of how MA induces neurotoxicity is still incomplete, but it is likely that the formation of reactive oxygen species is a contributory factor (Quinton and Yamamoto, 2006; Fleckenstein et al., 1997; Yamamoto and Zhu, 1998) . In the present study, MA treatment may have triggered increased catabolism of DOPAC via hydrogen peroxide oxidation in the striatum, which would promote neurotoxicity. A reduction of dopamine metabolites and dopamine have previously been demonstrated in mouse striatum 3 days after MA binge-like treatment with a substantially higher dose (10 mg × 4 doses, 2 h apart) than used in our study (Imam et al., 1999) . Another study by the same group showed a dose-response effect of MA on dopamine and its metabolites in rat striatum. A single dose of 10 mg/ kg (and up to 40 mg/kg) reduced dopamine, DOPAC and HVA in the striatum, but 5 mg/kg reduced DOPAC alone (Imam and Ali, 2001) , which is consistent with our observation. Many studies have previously shown long term damage to dopaminergic nerve terminals in the striatum (McCann et al., 1998; Volkow et al., 2001) . It would be of interest to investigate further the link between DOPAC levels and neurotoxicity in future work.
Tyrosine hydroxylase gene expression is closely controlled by transcriptional and post-transcriptional mechanisms (Kumer and Vrana, 1996; Wong and Tank, 2007; Daubner et al., 2011) . MA induced dopamine release is thought to increase cAMP activity, resulting in CREB phosphorylation, which can increase tyrosine hydroxlase expression (Piech-Dumas and Tank, 1999) . In this study, there was no change observed in the level of the dopamine precursor L-DOPA in any brain region assessed, but the expression of tyrosine hydroxylase in fibres in the frontal cortex (area fraction of tyrosine hydroxylase containing fibres in the frontal cortex) was increased 2 h after the binge-like MA dosing, suggesting an upregulation of TH activity in the frontal cortex. The frontal cortex was chosen because the most pronounced changes in dopamine turnover were observed in that area in the current study, but it would be of great interest to assess the impact of MA on the expression of tyrosine hydroxylase in fibres in other brain regions, particularly the amygdala and striatum in future work.
The frontal cortex is a region known to influence motor function, decision-making and emotion, important features to be considered in drug addiction. Methamphetamine-impairs cognition and changes in behaviour following methamphetamine administration to nonhuman primates is produced in part by neuronal changes in the frontal lobes (Coutinho et al., 2008) . The Frontal cortex is also important in reward via the mesocortical pathway. Likewise, the amygdala is a very important brain region involved with the expression and perception of emotion, and has been implicated in the pathophysiology of affective disorders and drug addiction. The prefrontal cortex is involved in higher-order cognition and emotion and taking into account that drug addiction involves maladaptive behaviour, the prefrontal cortex is a logical structure in this context (Spinella, 2003) . There are some lines of evidence that implicate prefrontal and limbic dysfunction with addiction. Polysubstance abusers show a smaller prefrontal gray matter than controls (Liu et al., 1998) and psychostimulant abusers have decreased gray matter in brain regions including the ventromedial orbitofrontal cortex, anterior cingulate cortex and superior temporal cortex relative to controls (Franklin et al., 2002) . It would be of great interest to study the longer -term changes in dopaminergic neurons in a model of MA addiction.
Interestingly, our observations at the 2 h time point showing a significant reduction in the volume of tyrosine hydroxylase cell bodies in the substantia nigra and the ventral tegmental area correlates with the time point when the rats exhibited significant hyperthermia. The decrease in the size of cell bodies in the VTA and SN could be directly caused by the increase in body temperature seen 2 h after the last dose of MA -as the temperature increases cells can lose water and shrink. Fig. 4 . Effect of methamphetamine (MA) on area fraction of tyrosine hydroxylase containing fibres in the frontal cortex over time. Results were analysed by one-way ANOVA followed by Dunnett's post hoc analysis and are expressed as mean ± S.E.M. (n = 6), ⁎ p < 0.05 vs control. Inset shows representative images (x20 magnification) of tyrosine hydroxylase containing fibres in frontal cortex.
Hyperthermia is a well recognized feature of neurotoxicity induced by amphetamine and its derivates such as MA (Miller and O'Callaghan, 1994; Brown and Kiyatkin, 2004; Freedman et al., 2005) . Changes in body temperature following MA administration can be a good indicator of neurotoxicity, as severe hyperthermia has been correlated with neurodegeneration (Davidson et al., 2001) . Hyperthermia produced by MA may cause induction of heat shock protein (HSP)-72 and trigger the ultimate depletion of dopamine concentration (Kuperman et al., 1997) . Furthermore, studies have shown that when hyperthermia is prevented by placing the rats in a cold environment, dopaminergic deficits are significantly attenuated (Bowyer et al., 1992) . The mechanism by which MA and amphetamine like substances increase body temperature is not fully clarified, but studies have shown that hyperthermia can be prevented by a dopamine synthesis inhibitor (α-methyl-p-tyrosine), a dopamine D1 receptor antagonist (SCH23390) or a dopamine D2 receptor antagonist (eticlopride) (Metzger et al., 2000; Albers and Sonsalla, 1995) , indicating that dopamine and dopamine receptors play an important role in MA-induced hyperthermia. Further work directly correlating body temperature to cell volume changes in dopaminergic neurons would be very valuable, as would further study into the mechanism involved in the effect.
It is also of interest to note that cell bodies of tyrosine hydroxylase expressing neurons in the SN were significantly increased in size 48 h following binge drug taking regimen, which potentially may trigger long lasting change in the striatum. As previously mentioned, MA has been demonstrated to alter nerve terminal endings in the striatum in rats (Thomas et al., 2004) , to cause enlargement of striatal volume in adult abusers of the drug and a reduction in striatal volume in children exposed to MA prenatally (Chang et al., 2007) . The findings in this study suggest that increased catabolism of DOPAC leading to reactive oxygen species generation may be involved, although this needs to be confirmed directly. Further study investigating if the early changes observed in the current study are the initial steps in the development of neurotoxic changes in response to MA would be very valuable.
Binge-like MA dosing had a time-and region-specific effect on the dopaminergic system in the rat brain. It also exerted time-dependent effects on the expression of tyrosine hydroxlase in fibres in the frontal cortex, and also on the cell bodies of tyrosine hydroxylase containing neurons in the substantia nigra and ventral tegmentum. These findings collectively highlight the importance of the dopaminergic system in MA induced effects and toxicity, and also identify the frontal cortex, amygdala and striatum as important regions that undergo early changes in response to binge-like MA dosing. Further study will provide valuable insights into the role of these brain regions in MA addiction and also the extent and mechanism of neurotoxicity caused by the drug.
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